(Q43530254)

English

Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305).

scientific article published on 11 December 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

chemoradiotherapy

0 references

1 reference

ChEBI release 2020-05-28

anaplastic astrocytoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Kuniaki Ogasawara

5

object named as

Kuniaki Ogasawara

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

author name string

Soichiro Shibui

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Yoshitaka Narita

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Junki Mizusawa

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Takaaki Beppu

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Yutaka Sawamura

6

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Hiroyuki Kobayashi

7

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Ryo Nishikawa

8

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Kazuhiko Mishima

9

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Yoshihiro Muragaki

10

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Takashi Maruyama

11

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Junichi Kuratsu

12

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Hideo Nakamura

13

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Masato Kochi

14

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Yoshio Minamida

15

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Toshiaki Yamaki

16

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Toshihiro Kumabe

17

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Teiji Tominaga

18

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Takamasa Kayama

19

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Kaori Sakurada

20

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Motoo Nagane

21

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Keiichi Kobayashi

22

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Hirohiko Nakamura

23

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Tamio Ito

24

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Takahito Yazaki

25

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Hikaru Sasaki

26

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Katsuyuki Tanaka

27

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Hideaki Takahashi

28

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Akio Asai

29

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Tomoki Todo

30

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Toshihiko Wakabayashi

31

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Jun Takahashi

32

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Shingo Takano

33

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Takamitsu Fujimaki

34

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Minako Sumi

35

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Yasuji Miyakita

36

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Yoichi Nakazato

37

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Akihiro Sato

38

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Haruhiko Fukuda

39

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Kazuhiro Nomura

40

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

publication date

11 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

71

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

511-521

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

Radiation therapy combined with radiosensitizing agents for cerebral glioblastoma in adults.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

Effects of ACNU and radiotherapy on malignant glioma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2041-5

21 January 2018

Identifiers

10.1007/S00280-012-2041-5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43530254&oldid=2206104712"